The development of precision immunosuppressive regimens, incorporating clinical variables such as age, MG phenotype (ocular/generalized), autoantibody profile (AChR/MuSK/LRP4), and comorbidity burden, warrants rigorous investigation, particularly regarding optimization strategies during concurrent respiratory infections. Here, MUSK is linked to myasthenia gravis.